David M. Albala, MD, presented “Telesurgery for Prostate Cancer: Where Are We in 2024? – This Is a Novel Topic and Gaining Traction Around the World” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Albala, David M. “Telesurgery for Prostate Cancer: Where Are We in 2024? – This Is a Novel Topic and Gaining Traction Around the World.” August 2024. Accessed Mar 2026. https://grandroundsinurology.com/telesurgery-for-prostate-cancer-where-are-we-in-2024-this-is-a-novel-topic-and-gaining-traction-around-the-world/
Telesurgery for Prostate Cancer: Where Are We in 2024? – This Is a Novel Topic and Gaining Traction Around the World – Summary
David M. Albala, MD, explores the future of telesurgery, particularly in prostate cancer, emphasizing the intersection of medicine and technology. Dr. Albala relays a history of robotic surgery, beginning in the 1980s with the development of the Da Vinci Robotic System, and the Lindbergh operation in 1991.
In this 14-minute presentation, Dr. Albala highlights the importance of telesurgery in leveling global healthcare disparities. He also notes the successful implementation of telesurgery in urological procedures, such as prostatectomies and partial nephrectomies.
Despite the technological advancements, challenges persist, including economic constraints, patient awareness, and resistance to adoption. The presentation underscores the need for reliable and secure systems and robust training programs to ensure the safe implementation of telesurgery.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
David M. Albala, MD, is a Chief of Urology at Crouse Hospital in Syracuse, New York. Dr. Albala is considered a national and international authority in laparoscopic and robotic urological surgery. His clinical interests include minimally invasive treatments for benign prostatic hypertrophy (BPH), the use of fibrin sealants in surgery, and robotic urologic surgery.
Dr. Albala earned his medical degree at Michigan State University in East Lansing. He completed a residency in Surgery at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. He then completed a fellowship in Endourology at Washington University in St. Louis, Missouri. Under the direction of Ralph V. Clayman, Dr. Albala was part of the team that performed the first laparoscopic nephrectomy in humans.
Dr. Albala is a past White House Fellow (1995-1996), who acted as a special assistant to Federico Peña, Secretary of Transportation, on classified and unclassified public health related issues. He has been a visiting professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. He has done operative demonstrations in over 32 countries and 23 states. Dr. Albala has over 215 publications in peer-reviewed journals and has authored 3 textbooks in endourology and 4 books in general urology. He is currently the Editor-in-Chief of theJournal of Robotic Surgeryand serves on the editorial board forCurrent Opinions in Urology, Reviews in Urology,andUrology Index and Reviews. In addition, he serves as a reviewer for 8 other surgical journals. He is currently on the Board of Directors of the Large Urology Group Practice Association (LUGPA). Dr. Albala is also currently the Visiting Professor of Urology at SUNY Downstate Health Sciences University, College of Medicine. Dr. Albala has been identified (by a Stanford University-led study) as one of the top 2% of scientists in the world.
